Cargando…

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation

Novel, neuroprotective uses of Copaxone (generic name: glatiramer acetate—GA) are being examined, primarily in neurological conditions involving cognitive decline. GA is a well-studied synthetic copolymer that is FDA-approved for immune-based treatment of relapsing remitting multiple sclerosis (RRMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasindi, Arielle, Fuchs, Dieu-Trang, Koronyo, Yosef, Rentsendorj, Altan, Black, Keith L., Koronyo-Hamaoui, Maya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099707/
https://www.ncbi.nlm.nih.gov/pubmed/35563884
http://dx.doi.org/10.3390/cells11091578
_version_ 1784706673003200512
author Kasindi, Arielle
Fuchs, Dieu-Trang
Koronyo, Yosef
Rentsendorj, Altan
Black, Keith L.
Koronyo-Hamaoui, Maya
author_facet Kasindi, Arielle
Fuchs, Dieu-Trang
Koronyo, Yosef
Rentsendorj, Altan
Black, Keith L.
Koronyo-Hamaoui, Maya
author_sort Kasindi, Arielle
collection PubMed
description Novel, neuroprotective uses of Copaxone (generic name: glatiramer acetate—GA) are being examined, primarily in neurological conditions involving cognitive decline. GA is a well-studied synthetic copolymer that is FDA-approved for immune-based treatment of relapsing remitting multiple sclerosis (RRMS). Clinical studies have explored the potential mechanism of action (MOA) and outcomes of GA immunization in patients. Furthermore, results from these and animal studies suggest that GA has a direct immunomodulatory effect on adaptive and innate immune cell phenotypes and responses. These MOAs have been postulated to have a common neuroprotective impact in several neuroinflammatory and neurodegenerative diseases. Notably, several clinical studies report that the use of GA mitigated MS-associated cognitive decline. Its propensity to ameliorate neuro-proinflammatory and degenerative processes ignites increased interest in potential alternate uses such as in age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease (AD). Preclinical studies are exploring less frequent subcutaneous administration of GA, such as once weekly or monthly or a single dosing regimen. Indeed, cognitive functions were found to be either preserved, reversed, or improved after the less frequent treatment regimens with GA in animal models of AD. In this systematic review, we examine the potential novel uses of GA across clinical and pre-clinical studies, with evidence for its beneficial impact on cognition. Future investigation in large-size, double-blind clinical trials is warranted to establish the impact of GA immunomodulation on neuroprotection and cognitive preservation in various neurological conditions.
format Online
Article
Text
id pubmed-9099707
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90997072022-05-14 Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation Kasindi, Arielle Fuchs, Dieu-Trang Koronyo, Yosef Rentsendorj, Altan Black, Keith L. Koronyo-Hamaoui, Maya Cells Review Novel, neuroprotective uses of Copaxone (generic name: glatiramer acetate—GA) are being examined, primarily in neurological conditions involving cognitive decline. GA is a well-studied synthetic copolymer that is FDA-approved for immune-based treatment of relapsing remitting multiple sclerosis (RRMS). Clinical studies have explored the potential mechanism of action (MOA) and outcomes of GA immunization in patients. Furthermore, results from these and animal studies suggest that GA has a direct immunomodulatory effect on adaptive and innate immune cell phenotypes and responses. These MOAs have been postulated to have a common neuroprotective impact in several neuroinflammatory and neurodegenerative diseases. Notably, several clinical studies report that the use of GA mitigated MS-associated cognitive decline. Its propensity to ameliorate neuro-proinflammatory and degenerative processes ignites increased interest in potential alternate uses such as in age-related macular degeneration (AMD), amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease (AD). Preclinical studies are exploring less frequent subcutaneous administration of GA, such as once weekly or monthly or a single dosing regimen. Indeed, cognitive functions were found to be either preserved, reversed, or improved after the less frequent treatment regimens with GA in animal models of AD. In this systematic review, we examine the potential novel uses of GA across clinical and pre-clinical studies, with evidence for its beneficial impact on cognition. Future investigation in large-size, double-blind clinical trials is warranted to establish the impact of GA immunomodulation on neuroprotection and cognitive preservation in various neurological conditions. MDPI 2022-05-07 /pmc/articles/PMC9099707/ /pubmed/35563884 http://dx.doi.org/10.3390/cells11091578 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kasindi, Arielle
Fuchs, Dieu-Trang
Koronyo, Yosef
Rentsendorj, Altan
Black, Keith L.
Koronyo-Hamaoui, Maya
Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
title Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
title_full Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
title_fullStr Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
title_full_unstemmed Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
title_short Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
title_sort glatiramer acetate immunomodulation: evidence of neuroprotection and cognitive preservation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099707/
https://www.ncbi.nlm.nih.gov/pubmed/35563884
http://dx.doi.org/10.3390/cells11091578
work_keys_str_mv AT kasindiarielle glatirameracetateimmunomodulationevidenceofneuroprotectionandcognitivepreservation
AT fuchsdieutrang glatirameracetateimmunomodulationevidenceofneuroprotectionandcognitivepreservation
AT koronyoyosef glatirameracetateimmunomodulationevidenceofneuroprotectionandcognitivepreservation
AT rentsendorjaltan glatirameracetateimmunomodulationevidenceofneuroprotectionandcognitivepreservation
AT blackkeithl glatirameracetateimmunomodulationevidenceofneuroprotectionandcognitivepreservation
AT koronyohamaouimaya glatirameracetateimmunomodulationevidenceofneuroprotectionandcognitivepreservation